Chronic lymphocytic leukemia is a slow-growing blood cancer that starts in white blood cells called lymphocytes

Chronic lymphocytic leukemia (CLL) begins when bone marrow produces too many immature lymphocytes—a type of white blood cell that normally fights infection. Unlike acute leukemias, which develop rapidly, CLL grows slowly over months or years. The abnormal cells accumulate in the blood and lymph nodes, crowding out healthy blood cells. Many people have no symptoms when CLL is first detected; it is often found by chance during a blood test for another reason.

CLL almost always occurs in adults, typically those over 70, though it can develop at younger ages. It is more common in men than women. The disease progresses at different rates in different people—some remain stable for years with little or no treatment, while others experience faster changes that require intervention.

Key Takeaways

  • CLL develops when bone marrow makes too many lymphocytes, which accumulate slowly in blood and lymph nodes over time.
  • Many people have no symptoms when CLL is discovered and may not need treatment immediately, even after diagnosis.
  • Blood tests showing elevated white blood cell counts and lymphocyte percentages are how CLL is typically found.
  • Doctors use staging systems and genetic markers to predict how fast the disease will progress and guide treatment decisions.
  • Treatment options range from watchful waiting to chemotherapy, targeted drugs, and immunotherapy, depending on how the disease behaves.

How CLL develops in bone marrow and blood

Bone marrow is the spongy tissue inside bones where all blood cells are made. In CLL, something goes wrong in the DNA of a single lymphocyte, causing it to divide repeatedly without the normal stop signals. These abnormal cells are clones—identical copies of the original mutated cell. Over time, they outnumber healthy lymphocytes and other white blood cells.

The abnormal cells accumulate first in the blood, which is why a simple blood test often catches CLL. They also collect in lymph nodes (small bean-shaped organs throughout the body that filter fluid), the spleen, and sometimes the liver. Because CLL grows slowly, people may have millions of abnormal cells circulating for months or years before noticing anything wrong.

Why CLL is called "chronic" and what that means for progression

The word "chronic" means the disease develops slowly, in contrast to acute leukemias that progress rapidly over weeks. This slow pace is actually one reason many people with CLL live for years after diagnosis without needing treatment. Some people die from other causes before CLL ever becomes a serious problem.

However, "slow" does not mean "stopped." CLL will eventually progress in most people, though the timeline varies widely. Some patients remain stable for 10 or 20 years; others see changes within a few years. Doctors monitor this progression through blood counts and physical exams, watching for signs that treatment should begin.

Symptoms you might notice, or might not notice at all

Many people with CLL have no symptoms at diagnosis. The disease is found when a routine blood test shows an unusually high white blood cell count. This is why CLL is sometimes called a "silent" disease in its early stages.

When symptoms do appear, they may include fatigue, shortness of breath, easy bruising or bleeding, frequent infections, or swollen lymph nodes in the neck, armpit, or groin. Swelling of the spleen or liver can cause a feeling of fullness or discomfort in the upper left abdomen. These symptoms develop gradually and may be mild enough that people attribute them to other causes.

How doctors diagnose CLL

Diagnosis begins with a complete blood count (CBC), a standard blood test that measures different types of blood cells. In CLL, the CBC shows a high number of white blood cells, with lymphocytes making up an unusually large percentage. A second test called flow cytometry identifies the specific characteristics of these cells and confirms they are abnormal lymphocytes.

Doctors may also order a bone marrow biopsy, where a small sample of marrow is removed from the hip bone and examined under a microscope. This shows how many abnormal cells are present in the marrow itself. Imaging tests like ultrasound or CT scan can reveal whether lymph nodes or the spleen are enlarged.

Genetic markers that predict how fast CLL will progress

Not all CLL cells are identical at the genetic level. Doctors test for specific mutations and chromosomal changes that influence how aggressively the disease behaves. Two of the most important markers are del(17p) and TP53 mutations, which are associated with faster progression and poorer response to standard treatments. Del(13q), by contrast, is associated with slower progression and longer survival.

Another marker is IGHV mutation status, which reflects whether certain genes in the cancer cells have been altered. Mutated IGHV is generally associated with slower disease, while unmutated IGHV suggests faster progression. These markers help doctors predict which patients may remain stable for years and which may need treatment sooner.

Staging systems that describe how far CLL has spread

Doctors use staging to describe the extent of disease. The most common system in the United States is the Rai staging system, which has five stages (0 through 4) based on lymphocyte counts and whether lymph nodes, spleen, or liver are enlarged, and whether red blood cells or platelets are low.

Stage 0 means elevated lymphocytes but no enlarged nodes or organs and normal blood counts. Stage 1 adds enlarged lymph nodes. Stage 2 includes enlarged spleen or liver. Stage 3 means red blood cell counts are low. Stage 4 means platelet counts are low. Early-stage CLL (0 and 1) often requires no immediate treatment, while later stages may need intervention sooner. Staging combined with genetic markers gives doctors a clearer picture of what to expect.

Treatment approaches depend on how the disease behaves

Not everyone with CLL needs treatment right away. Many people with early-stage disease and stable blood counts follow a strategy called watchful waiting or active surveillance—regular blood tests and physical exams without chemotherapy or other drugs. This approach avoids side effects while the disease remains slow-growing.

When treatment becomes necessary, options include chemotherapy drugs (such as fludarabine or chlorambucil), targeted drugs that attack specific proteins on CLL cells (such as ibrutinib or venetoclax), and immunotherapy drugs that help the immune system recognize and kill cancer cells. Combination treatments are often more effective than single drugs. The choice depends on the patient's age, overall health, genetic markers, and how the disease has progressed.

Frequently Asked Questions

Is CLL the same as acute lymphocytic leukemia?

No. Acute lymphocytic leukemia (ALL) develops rapidly over weeks and requires immediate treatment. CLL develops slowly over months or years and may not need treatment for a long time. They arise from different types of lymphocytes and have very different outlooks.

Can you live a normal life with CLL?

Many people do, especially in early stages. Some remain stable for years without treatment and experience no symptoms. Others eventually need treatment but continue working and living normally during and after therapy. Life expectancy varies widely depending on age, genetic markers, and how the disease progresses.

Does CLL run in families?

CLL is not inherited in the way genetic disorders are passed down. However, having a close relative with CLL slightly increases your risk of developing it. The disease itself results from mutations that occur in a single cell during a person's lifetime, not from mutations inherited from parents.

What causes CLL?

The exact cause is unknown. Age is the strongest risk factor—CLL is rare before age 50 and becomes more common with age. Exposure to certain chemicals and some genetic factors may increase risk, but most people with CLL have no known exposure or family history.

Will CLL turn into a more aggressive cancer?

In a small percentage of people, CLL can transform into a more aggressive lymphoma called Richter transformation. This happens in roughly 5 percent of CLL cases. Most people with CLL do not experience this transformation and die from other causes or live with stable disease for many years.